Status:
AVAILABLE
Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients
Lead Sponsor:
AVM Biotechnology Inc
Conditions:
Glioblastoma
Squamous Cell Carcinoma
Eligibility:
All Genders
Brief Summary
AVM Biotechnology, Inc., provides immunomodulatory AVM0703 to solid tumor and blood cancer patients upon request by a US licensed MD or DO. As of July 2024, 37 patients have been treated through this ...
Eligibility Criteria
Inclusion
- \-
Exclusion
- \-
Key Trial Info
Start Date :
Trial Type :
EXPANDED_ACCESS
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT05974410
Last Update
October 2 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.